The Pharmacology and Clinical Potential of Prostacyclin

  • S. Moncada
  • J. R. Vane


Smith & Willis (1970) showed that aggregating platelets release, among other products, prostaglandins of the E and F type. Shortly afterwards it was shown that aspirin-like drugs inhibit prostaglandin biosynthesis (Vane, 1971; Ferreira, Moncada & Vane, 1971; Smith & Willis, 1971) and as a result the general theory was proposed (Vane, 1971) that this enzyme inhibition accounts for the anti-inflammatory effects (and perhaps the side effects) of aspirin-like drugs. Since then, substantial evidence to support this theory has accumulated and it is now widely accepted that the analgesic, anti-pyretic and anti-inflammatory effects of aspirin-like drugs are mediated via inhibition of prostaglandin biosynthesis (Vane, 1976; Moncada & Vane, 1979a).


Arachidonic Acid Platelet Aggregation Bleeding Time Renin Release Prostaglandin Endoperoxide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amezcua, J-L., O’Grady, J., Salmon, J. A. & Moncada, S. (1979). Prolonged paradoxical effect of aspirin on platelet behaviour and bleeding time in man. Thromb. Res., 16, 69–79.PubMedCrossRefGoogle Scholar
  2. Amezcua, J-L., Parsons, M. & Moncada, S. (1978). Unstable metabolites of arachidonic acid, aspirin and the formation of the haemostatic plug. Thromb. Res., 13, 477–488.PubMedCrossRefGoogle Scholar
  3. Armstrong, J. M, Chappie, D. J., Dusting, G. J., Hughes, R., Moncada, S. & Vane, J. R. (1977). Cardiovascular actions of prostacyclin (PGI2) in chloralose anaesthetized dogs. Brit. J. Pharmac, 61, 136p.Google Scholar
  4. Armstrong, J. M., Lattimer, N., Moncada, S. & Vane, J. R. (1978). Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prostaglandin F1α with those of prostaglandin E2 in rats and rabbits. Brit. J. Pharmac, 62, 125–130.CrossRefGoogle Scholar
  5. Ashida, S-I. & Abiko, Y. (1978). Effect of ticlopidine and acetylsalicylic acid on generation of prostaglandin I2 like substance in rat arterial tissue. Thromb. Res., 13, 901–908.PubMedCrossRefGoogle Scholar
  6. Baenziger, N. L., Dillender, M. J. & Majerus, P. (1977). Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandin. Biochem. Biophys. Res. Commun., 18, 294–301.CrossRefGoogle Scholar
  7. Baumgartner, H. R. & Tschopp, Th.B. (1979). Platelet interaction with aortic subendothelium (S.E.) in vitro. Locally produced PGI2 inhibits adhesion and formation of mural thrombi in flowing blood. Thrombosis and Haemostasis Abstracts. VII International Congress on Thrombosis and Haemostasis, pp. 6.Google Scholar
  8. Blackwell, G. J., Flower, R. J., Russell-Smith, N., Salmon, J. A., Thorogood, P. B. & Vane, J. R. (1978). l-n-Butylimidazole: A potent and selective inhibitor of ‘thromboxane synthetase’. Brit. J. Pharmac, 64, 436p.Google Scholar
  9. Blajchman, M. A., Senyi, A. F., Hirsh, J., Surya, Y., Buchanan, M. & Mustard, J. F., (1979). Shortening of the bleeding time in rabbits by hydrocortisone caused by inhibition of prostacyclin generation by the vessel wall. J. clin. Invest, 63, 1026–1035.PubMedCentralPubMedCrossRefGoogle Scholar
  10. Block, A. J., Feinberg, H., Herbaczynska-Cedro, K. & Vane, J. R. (1975). Anoxia induced release of prostaglandins in rabbit isolated heart. Circulation Res., 36, 34–42.PubMedCrossRefGoogle Scholar
  11. Bolger, P. M., Eisner, G. M., Ramwell, P. W. & Slotkoff, L. M. (1978). Renal actions of prostacyclin. Nature, 271, 457–469.Google Scholar
  12. Boullin, D. J., Bunting, S., Blaso, W. P., Hunt, T. M. & Moncada, S. (1979). Responses of human and baboon arteries to prostaglandin endoperoxides and biologically generated and synthetic prostacyclin: Their relevance to cerebral arterial spasm in man. Brit. J. clin. Pharmac, 7, 139–147.CrossRefGoogle Scholar
  13. Bunting, S., Gryglewski, R., Moncada, S. & Vane, J. R. (1976a). Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins, 12, 897–913.PubMedCrossRefGoogle Scholar
  14. Bunting, S. & Moncada, S. (1980). Prostacyclin by preventing platelet activation prolongs activated clotting time in blood and platelet rich plasma and potentiates the anticoagulant effect of heparin. Brit. J. Pharmac, 69, 268p–269p.Google Scholar
  15. Bunting, S., Moncada, S., Reed, P., Salmon, J. A. & Vane, J. R. (1978). An antiserum to 5, 6-dihydro prostacyclin (PGI1) which also binds prostacyclin. Prostaglandins, 15, 565–574.PubMedCrossRefGoogle Scholar
  16. Bunting, S., Moncada, S. & Vane, J. R. (1976b). The effects of prostaglandin endoperoxides and thromboxane A2 on strips of rabbit coeliac artery and other smooth muscle preparations. Brit. J. Pharmac, 57, 462p.Google Scholar
  17. Bunting, S., Moncada, S. & Vane, J. R. (1977). Antithrombotic properties of vascular endothelium. Lancet, 2, 1075–1076.PubMedCrossRefGoogle Scholar
  18. Bunting, S, Moncada, S., Vane, J. R., Woods, H. F. & Weston, M. J. (1979). Prostacyclin improves haemocompatibility during charcoal haemoperfusion. In Prostacyclin, ed. Vane, J. R. & Bergstrom, S., pp 361–369. New York: Raven Press.Google Scholar
  19. Burch, J. W., Stanford, N. & Majerus, P. W. (1978). Inhibition of platelet prostaglandin synthetase by oral aspirin. J. clin. Invest, 61, 314–319.PubMedCentralPubMedCrossRefGoogle Scholar
  20. Carlson, L. A. & Olsson, A. G. (1976). Intravenous prostaglandin E1 in severe peripheral vascular disease. Lancet, 2, 810.PubMedCrossRefGoogle Scholar
  21. Chappie, D. J., Dusting, G. J., Hughes, R. & Vane, J. R. (1978). A vagal reflex contributes to the hypotensive effect of prostacyclin in anaesthetized dogs. J. Physiol., 281, 43–44p.Google Scholar
  22. Chappie, D. J., Dusting, G. J., Hughes, R. & Vane, J. R. (1980). Some direct and reflex cardiovascular actions of prostacyclin (PGI2) and PGE2 in anaesthetized dogs. Brit. J. Pharmac, 68, 437–447.CrossRefGoogle Scholar
  23. Chierchia, S., Ciabattoni, G., Cinotti, G., Maseri, A., Patrono, C., Pulgiese, F., Distante, A., Simonetti, I. & Bernini, W. (1979). Haemodynamic and anti-aggregatory effects of prostacyclin (PGI2) in the healthy man. Circulation, 59 and 60, Supp. II p 83.Google Scholar
  24. Cho, M. J. & Allen, M. A. (1978). Chemical stability of prostacyclin in aqueous solution. Prostaglandins, 15, 943–954.PubMedCrossRefGoogle Scholar
  25. Christofinis, G. J., Moncada, S., Bunting, S. & Vane, J. R. (1979). Prostacyclin (PGI2) release by rabbit aorta and human umbilical vein endothelial cells after prolonged subculture. In Prostacyclin, ed. Vane, J. R. & Bergstrom, S., pp 77–84. New York: Raven Press.Google Scholar
  26. Coceani, F., Bishai, I., White, E., Bodach, E. & Olley, P. M. (1978). Action of prostaglandins, endoperoxides and thromboxanes on the lamb ductus arteriosus. Am. J. Physiol, 234, H117–H122.Google Scholar
  27. Czervionke, R. L., Hoak, J. C. & Fry, G. L. (1978). Effect of aspirin on thrombin-induced adherence of platelets to cultured cells from the blood vessel walls. J. clin. Invest., 62, 847–856.PubMedCentralPubMedCrossRefGoogle Scholar
  28. Czervionke, R. L., Smith, J. B., Fry, G. L. & Hoak, J. C. (1979). Inhibition of prostacyclin by treatment of endothelium with aspirin. J. clin. Invest., 63, 1089–1092.PubMedCentralPubMedCrossRefGoogle Scholar
  29. Data, J. L., Crump, W. J., Hollifield, J. W., Frolich, J. C. & Nies, A. S. (1976). Prostaglandins: A role in baroreceptor control of renin release. Clin. Res., 24, 397 A.Google Scholar
  30. Davison, E. M., Ford-Hutchinson, A. W., Smith, M. J. H. & Walker, J. R. (1978). The release of thromboxane B2 by rabbit peritoneal polymorphonuclear leukocytes. Brit. J. Pharmac, 63, 407 p.Google Scholar
  31. De Dekere, E. A. M., Nugteren, D. H. & Ten Hoor, F. (1977). Prostacyclin is the major prostaglandin released from the isolated perfused rabbit and rat heart. Nature, 268, 160–163.CrossRefGoogle Scholar
  32. Dollery, C. T., Friedman, L. A., Hensby, C. N., Kohner, E., Lewis, P. J., Porta, M. & Webster, J. (1979). Circulating prostacyclin may be reduced in diabetes. Lancet, 2, 1365.PubMedCrossRefGoogle Scholar
  33. Dusting, G J., Chappie, D. J., Hughes, R., Moncada, S. & Vane, J. R. (1978a). Prostacyclin induces coronary vasodilatation in anaesthetised dogs. Cardiovascular Res., 12, 720–730.CrossRefGoogle Scholar
  34. Dusting, G. J., Moncada, S. & Vane, J. R. (1977a). Disappearance of prostacyclin in the circulation of the dog. Brit. J. Pharmac, 62, 514–415 p.Google Scholar
  35. Dusting, G J., Moncada, S. & Vane, J. R. (1977b). Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachidonic acid. Prostaglandins, 13, 3–15.PubMedCrossRefGoogle Scholar
  36. Dusting, G J., Moncada, S. & Vane, J. R. (1977c). Prostacyclin is a weak contractor of coronary arteries in the pig. Eur. J. Pharmac, 45, 301–304.CrossRefGoogle Scholar
  37. Dusting, G. J., Moncada, S. & Vane, J. R. (1978b). Vascular actions of arachidonic acid and its metabolites in perfused mesenteric and femoral beds of the dog. Eur. J. Pharmac, 49, 65–72.CrossRefGoogle Scholar
  38. Dusting, G. J., Moncada, S. & Vane, J. R. (1978c). Recirculation of prostacyclin (PGI2) in the dog. Brit. J. Pharmac., 64, 315–320.CrossRefGoogle Scholar
  39. Ferreira, S. H., Moncada, S. & Vane, J. R. (1971). Indomethacin and aspirin abolish prostaglandin release from the spleen. Nature New Biol., 231, 237–239.PubMedCrossRefGoogle Scholar
  40. Ferreira, S. H. & Vane, J. R. (1967). Prostaglandins: Their disappearance from and release into the circulation. Nature, 216, 868–873.PubMedCrossRefGoogle Scholar
  41. Fitzgerald, G. A., Friedman, L. A., Miyamori, I., O’Grady, J. & Lewis, P. J. (1979). A double-blind placebo controlled crossover study of prostacyclin in man. Life Sci., 25, 665–672.PubMedCrossRefGoogle Scholar
  42. Flower, R. J. (1978). Steroidal anti-inflammatory drugs as inhibitors of phospholipase A2. In Advances in Prostaglandin and Thromboxane Research, Vol. 3, ed. Paoletti, R.&. Samuelsson, B., pp. 105–112. New York: Academic Press.Google Scholar
  43. Friedenberg, W. R., Myers, W. O., Plotka, E. D., Beathard, J. N., Kummer, D. J., Gatlin, P. F., Stoiber, D. L., Ray, J. F. & Sautter, R. D. (1978). Platelet dysfunction associated with cardiopulmonary bypass. Ann. Thorac. Surg., 25, 298–305.PubMedCrossRefGoogle Scholar
  44. Frolich, J. C., Hollifield, J. W., Dormois, J. C., Frolich, B. L., Seyberth, H., Michelakis, A. M. & Oates, J. A. (1976). Suppression of plasma renin activity by indomethacin in man. Circulation Res., 39, 447–452.PubMedCrossRefGoogle Scholar
  45. Gerber, J. G., Branch, R. A., Nies, A. S., Gerkens, J. F., Shand, D. G., Hollifield, J. & Oates, J. A. (1978). Prostaglandins and renin release. II. Assessment of renin secretion following infusion of PGI2, E2 and D2 into the renal artery of anaesthetized dogs. Prostaglandins, 15, 81–88.PubMedCrossRefGoogle Scholar
  46. Gimson, A. E. S., Hughes, R. D., Mellon, P. J., Woods, H. F., Langley, P. G., Canalese, J., Williams, R. & Weston, M. J. (1980). Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure. Lancet, 1, 173–175.PubMedCrossRefGoogle Scholar
  47. Godal, H. C., Eika, C., Dybdahl, J. H., Daae, L. & Larsen, S. (1979). Aspirin and bleeding time. Lancet, 1, 1236.PubMedCrossRefGoogle Scholar
  48. Goldstein, I. M., Malmsten, C. L., Kaplan, H. B., Kindahl, H., Samuelsson, B. & Weissman, G. (1977). Thromboxane generation by stimulated human granulocytes: Inhibition by glucocorticoids and superoxide dismutase. Clin. Res., 25, 518A.Google Scholar
  49. Gordon, J. L. & Pearson, J. D. (1978). Effects of sulphinpyrazone and aspirin on prostaglandin I2 (prostacyclin) synthesis by endothelial cells. Brit. J. Pharmac., 64, 481–483.CrossRefGoogle Scholar
  50. Gorman, R. R., Bundy, G. L., Peterson, D. C., Sun, F. F., Miller, O. V. & Fitzpatrick, F. A. (1977a). Inhibition of human platelet thromboxane synthetase by 9, ll-azoprosta-5, 13-dienoic acid. Proc. Nat. Acad. Sci. USA, 74, 4007–4011.PubMedCentralPubMedCrossRefGoogle Scholar
  51. Gorman, R. R., Bunting, S. & Miller, O. V. (1977b). Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins, 13, 377–388.PubMedCrossRefGoogle Scholar
  52. Grenier, F. C. & Smith, W. L. (1978). Formation of 6-keto-PGF1 α by collecting tubule cells isolated from rabbit renal papillae. Prostaglandins, 16, 759–772.CrossRefGoogle Scholar
  53. Gryglewski, R. J., Korbut, R. & Ocetkiewicz, A. C. (1978a). De-aggregatory action of prostacyclin in vivo and its enhancement by theophylline. Prostaglandins, 15, 637–644.PubMedCrossRefGoogle Scholar
  54. Gryglewski, R. J., Korbut, R. & Ocetkiewicz, A. C. (1978b). Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature, 273, 765–767.PubMedCrossRefGoogle Scholar
  55. Gryglewski, R. J., Korbut, R., Ocetkiewicz, A. C. & Stachwa, R. (1978c). In vivo method for quantitation of anti-platelet potency of drugs. Arch. Pharmakol, 302, 25–30.CrossRefGoogle Scholar
  56. Gryglewski, R. J., Szczeklik, A. & Nizankowski, R. (1978d). Antiplatelet action of intravenous infusion of prostacyclin in man. Thromb. Res., 13, 153–163.PubMedCrossRefGoogle Scholar
  57. Gryglewski, R. J., Zmuda, A., Korbut, R., Krecioch, E. & Bieron, K. (1977). Selective inhibition of thromboxane A2 biosynthesis in blood platelets. Nature, 267, 627–628.PubMedCrossRefGoogle Scholar
  58. Gullner, H-G., Cerletti, C., Bartter, F. C., Smith, J. B. & Gill, J. R., Jr. (1979). Prostacyclin overproduction in Bartter’s syndrome. Lancet, 2, 767–768.PubMedCrossRefGoogle Scholar
  59. Hamberg, M. & Samuelsson, B. (1973). Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. Proc. Nat. Acad. Sci. USA, 70, 899–903.PubMedCentralPubMedCrossRefGoogle Scholar
  60. Hamberg, M. & Samuelsson, B. (1974). Novel transformations of arachidonic acid in human platelets. Proc. Nat. Acad. Sci. USA, 71, 3400–3404.PubMedCentralPubMedCrossRefGoogle Scholar
  61. Hamberg, M., Svensson, J. & Samuelsson, B. (1975). Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Nat. Acad. Sci. USA, 72, 2994–2998.PubMedCentralPubMedCrossRefGoogle Scholar
  62. Hamberg, M., Svensson, J., Wakabayashi, T. & Samuelsson, B.(1974). Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc. Nat. Acad. Sci. USA, 71, 345–349.PubMedCentralPubMedCrossRefGoogle Scholar
  63. Harrison, H. E., Reece, A. H. & Johnson, M. (1978). Decreased vascular prostacyclin in experimental diabetes. Life Sci., 23, 351–356.PubMedCrossRefGoogle Scholar
  64. Harter, H. R., Burch, J. W., Majerus, P. W., Standford, N., Pelmes, J. A., Anderson, C. B. & Weerts, C. A. (1979). Prevention of thromboembolism in patients of haemodialysis by low dose aspirin. New Eng. J. Med, 301, 577–579.PubMedCrossRefGoogle Scholar
  65. Hensby, C. N., Barnes, P. J., Dollery, C. T. & Dargie, H. (1979). Production of 6-oxo-PGF1 α by human lung in vivo. Lancet, 2, 1162–1163.PubMedCrossRefGoogle Scholar
  66. Heyns, A. Du P., van den Berg, D. J., Potgieter, G. M. & Retief, F. P. (1974). The inhibition of platelet aggregation by an aorta intima extract. Thromb. Diath. Haemorrh. (Stuttg.), 32, 417–431.Google Scholar
  67. Higgs, E. A., Moncada, S., Vane, J. R., Caen, J. P., Michel, H. & Tobelem, G. (1978). Effect of prostacyclin (PGI2) on platelet adhesion to rabbit arterial subendothelium. Prostaglandins, 16, 17–22.PubMedCrossRefGoogle Scholar
  68. Higgs, G. A., Bunting, S., Moncada, S. & Vane, J. R. (1976). Polymorphonuclear leukocytes produce thromboxane A2-like activity during phagocytosis. Prostaglandins, 12, 749–757.PubMedCrossRefGoogle Scholar
  69. Higgs, G. A., Cardinal, D. C., Moncada, S. & Vane, J. R. (1979). Microcirculatory effects of prostacyclin (PGI2) in hamster cheek pouch. Microvasc. Res., 18, 245–254.PubMedCrossRefGoogle Scholar
  70. Higgs, E. A., Higgs, G. A., Moncada, S. & Vane, J. R. (1978). Prostacyclin (PGI2) inhibits the formation of platelet thrombi in arterioles and venules of the hamster cheek pouch. Brit J. Pharmac., 63, 535–539.CrossRefGoogle Scholar
  71. Hill, T. W. K. & Moncada, S. (1979). The renal haemodynamic and excretory actions of prostacyclin and 6-oxo-PGF1 α in anaesthetized dogs. Prostaglandins, 17, 87–98.PubMedCrossRefGoogle Scholar
  72. Hill, T. W. K., Moncada, S. & Vane, J. R. (1978). Stimulation of renin release by prostacyclin (PGI2) in anaesthetised dogs. In Abstracts VII International Congress Pharmacology, Paris, July, 1978, pp. 343. Oxford: Pergamon Press.Google Scholar
  73. Hintze, T. H. & Kaley, G. (1977). Prostaglandins and the control of blood flow in the canine myocardium. Circulation Res., 40, 313–320.PubMedCrossRefGoogle Scholar
  74. Hintze, T. H., Kaley, G., Martin, E. G. & Messina, E. J. (1978). PGI2 induces bradycardia in the dog. Prostaglandins, 15, 712.Google Scholar
  75. Hyman, A. L., Kadowitz, P. J., Lands, W. E. M., Crawford, C. G., Fried, J. & Barton, J. (1978). Coronary vasodilator activity of 13, 14-dehydro prostacyclin methyl ester: Comparison with prostacyclin and other prostanoids. Proc. Nat. Acad. Sci. USA, 75, 3522–3526.PubMedCentralPubMedCrossRefGoogle Scholar
  76. Jobin, F. (1978). Acetylsalicylic acid, hemostasis and human thromboembolism. Sem. Thromb. Haemost. 4, 199–240.Google Scholar
  77. Johnson, M., Harrison, H. E., Raftery, A. T. & Elder, J. B. (1979). Vascular prostacyclin may be reduced in diabetes in man. Lancet, 1, 325–326.PubMedCrossRefGoogle Scholar
  78. Johnson, M., Reece, A. H. & Harrison, H. E. (1978). Decreased vascular prostacyclin in experimental diabetes. In Abstracts VII International Congress of Pharmacology, Paris, 1978, pp 342. Oxford: Pergamon Press.Google Scholar
  79. Johnson, R. A., Morton, D. R., Kinner, J. H., Gorman, R. R., McGuire, J. C., Sun, F. F., Whittaker, N., Bunting, S., Salmon, J., Moncada, S. & Vane, J. R. (1976). The chemical structure of prostaglandin X (prostacyclin). Prostaglandins, 12, 915–928.PubMedCrossRefGoogle Scholar
  80. Jorgensen, K. A., Olesen, A. S., Dyerberg, J. & Stoffersen, E. (1979). Aspirin and bleeding time: dependency of age. Lancet, 2, 302.PubMedCrossRefGoogle Scholar
  81. Kadowitz, P. J., Chapnick, B. M., Feigen, L. P., Hyman, A. L., Nelson, P. K. & Spannhake, E. W. (1978). Pulmonary and systemic vasodilator effects of the newly discovered prostaglandin, PGI2. J. app. Physiol., 45, 408–413.Google Scholar
  82. Kelton, J. G., Hirsch, J., Carter, C. J. & Buchanan, M. R. (1978). Thrombogenic effect of high dose aspirin in rabbits; relationship to inhibition of vessel wall synthesis of prostaglandin I2 like activity. J. clin. Invest., 62, 892–895.PubMedCentralPubMedCrossRefGoogle Scholar
  83. Korbut, R. & Moncada, S. (1978). Prostacyclin (PGI2) and thromboxane A2 interaction in vivo. Regulation by aspirin and relationship with antithrombotic therapy. Thromb. Res., 13, 489–500.PubMedCrossRefGoogle Scholar
  84. Kulkarni, P. S. & Eakins, K. E. (1976). N-0164 inhibits generation of thromboxane A2-like activity from prostaglandin endoperoxides by human platelet microsomes. Prostaglandins, 12, 465–469.PubMedCrossRefGoogle Scholar
  85. Kulkarni, P. S., Roberts, R. & Needleman, P. (1976). Paradoxical endogenous synthesis of a coronary dilating substance from arachidonate. Prostaglandins, 12, 337–353.PubMedCrossRefGoogle Scholar
  86. Lagarde, M. & Dechavanne, M. (1977). Increase of platelet prostaglandin cyclic endoperoxides in thrombosis. Lancet, 1, 88.PubMedCrossRefGoogle Scholar
  87. Larsson, C., Weber, P. & Anggard, E. (1974). Arachidonic acid increases and indomethacin decreases plasma renin activity in the rabbit. Eur. J. Pharmac., 28, 391–394.CrossRefGoogle Scholar
  88. Lefer, A. M., Ogletree, M. L., Smith, J. B., Silver, M. J., Nicolaou, K. G., Barnette, W. E. & Gasic, G. P. (1978). Prostacyclin: A potentially valuable agent for preserving myocardial tissues in acute myocardial ischaemia. Science, 200, 52–54.PubMedCrossRefGoogle Scholar
  89. Leffler, C. W. & Hessler, J. R. (1979). Pulmonary and systemic vascular effects of exogenous prostaglandin I2 in fetal lambs. Eur. J. Pharmac., 54, 37–42.CrossRefGoogle Scholar
  90. Levy, S. V. (1978). Contractile responses to prostacyclin (PGI2) of isolated human saphenous and rat venous tissue. Prostaglandins, 16, 93–97.PubMedCrossRefGoogle Scholar
  91. Lewy, R. I., Smith, J. B., Silver, M. J., Wiener, L. & Walinsky, P. (1979). Detection of thromboxane B2 in peripheral blood of patients with Prinzmetal’s angina. Prostaglandin Med., 2, 243–248.CrossRefGoogle Scholar
  92. Lieberman, G. E., Lewis, G. P. & Peters, T. J. (1977). A membrane-bound enzyme in rabbit aorta capable of inhibiting adenosine-diphosphate-induced platelet aggregation. Lancet, 2, 330–332.PubMedCrossRefGoogle Scholar
  93. Longmore, D. B., Bennett, G., Gueirrara, D., Smith, H., Bunting, S., Moncada, S., Reed, P., Read, N. G. & Vane, J. R. (1979). Prostacyclin: a solution to some problems of extracorporeal circulation. Lancet, 1, 1002–1005.PubMedCrossRefGoogle Scholar
  94. MacIntyre, D. E., Pearson, J. D. & Gordon, J. L. (1978). Stimulation of prostacyclin production in vascular cells. Nature, 271, 549–551.PubMedCrossRefGoogle Scholar
  95. Majerus, P. W. (1976). Why aspirin? Circulation, 54, 357–359.PubMedCrossRefGoogle Scholar
  96. Marcus, A. J. (1978). The role of lipids in platelet function with particular reference to the arachidonic acid pathway. J. Lipid Res., 19, 793–826.PubMedGoogle Scholar
  97. Masotti, G., Galanti, G., Poggesi, L., Abbate, R. & Neri Serneri, G. G. (1979). Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet, 2, 1213–1216.PubMedCrossRefGoogle Scholar
  98. Moncada, S., Bunting, S., Mullane, K. M., Thorogood, P., Vane, J. R., Raz, A. & Needleman, P. (1977a). Imidazole: A selective potent antagonist of thromboxane synthetase. Prostaglandins, 13, 611–618.PubMedCrossRefGoogle Scholar
  99. Moncada, S., Gryglewski, R. J., Bunting, S. & Vane, J. R. (1976a). An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature, 263, 663–665.PubMedCrossRefGoogle Scholar
  100. Moncada, S., Gryglewski, R. J., Bunting, S. & Vane, J. R. (1976b). A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins, 12, 715–733.PubMedCrossRefGoogle Scholar
  101. Moncada, S., Herman, A. G., Higgs, E. A. & Vane, J. R. (1977b). Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explantion for the antithrombotic properties of vascular endothelium. Thromb. Res., 11, 323–344.PubMedCrossRefGoogle Scholar
  102. Moncada, S., Korbut, R., Bunting, S. & Vane, J. R. (1978). Prostacyclin is a circulating hormone. Nature, 273, 767–768.PubMedCrossRefGoogle Scholar
  103. Moncada, S., Needleman, P., Bunting, S. & Vane, J. R. (1976c). Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. Prostaglandins, 12, 323–325.PubMedCrossRefGoogle Scholar
  104. Moncada, S. & Vane, J. R. (1977). The discovery of prostacyclin — a fresh insight into arachidonic acid metabolism. In Biochemical Aspects of Prostaglandins and Thromboxanes, ed. Kharasch, N. & Fried, J., pp 155–177. New York, San Francisco, London: Academic Press.Google Scholar
  105. Moncada, S. & Vane, J. R. (1978). Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Brit. med. Bull., 34, 129–135.PubMedGoogle Scholar
  106. Moncada, S. & Vane, J. R. (1979a). Mode of action of aspirin-like drugs. In Advances in Internal Medicine, Vol. 24, ed. Stollerman, G. H., pp 1–22. Chicago, London: Year Book Medical Publishers, Inc.Google Scholar
  107. Moncada, S. & Vane, J. R. (1979b). The role of prostacyclin in vascular tissue. Fed. Proc., 38, 62–66.Google Scholar
  108. Moriau, M., Masure, R., Hurlet, A., Debeys, C., Chalant, C., Poulot, R., Jaumain, P., Servaye-Kestens, Y., Ravaux, A., Louis, A. & Goenen, M. (1977). Haemostasis disorders in open heart surgery with extracorporeal circulation. Vox Sanguinis, 32, 41–51.PubMedCrossRefGoogle Scholar
  109. Mullane, K. M., Dusting, G. J., Salmon, J. A., Moncada, S. & Vane, J. R. (1979a). Biotransformation and cardiovascular effects of arachidonic acid in the dog. Eur. J. Pharmac., 54, 217–228.CrossRefGoogle Scholar
  110. Mullane, K. M., Moncada, S. & Vane, J. R. (1979b). Prostacyclin release induced by bradykinin may contribute to the anti-hypertensive action of angiotensin converting enzyme inhibitors. In 4th International Prostaglandin Congress p 84. Washington, D.C., May, 1979.Google Scholar
  111. Mustard, J. F. & Packham, M. A. (1975). Platelets, thrombosis and drugs. Drugs, 9, 19–76.PubMedCrossRefGoogle Scholar
  112. Needleman, P. (1976). The synthesis and function of prostaglandins in the heart. Fed. Proc., 35, 2376–2381.PubMedGoogle Scholar
  113. Needleman, P., Bronson, S. D., Wyche, A., Sivakoff, M. & Nicolaou, K. (1978). Cardiac and renal prostaglandin I2. J. clin. Invest., 61, 839–849.PubMedCentralPubMedCrossRefGoogle Scholar
  114. Needleman, P., Bryan, B., Wyche, A., Bronson, S. D., Eakins, K., Ferrendelli, J. A. & Minkes, M. (1977). Thromboxane synthetase inhibitors as pharmacological tools; differential biochemical and biological effects on platelet suspensions. Prostaglandins, 14, 897–907.PubMedCrossRefGoogle Scholar
  115. Needleman, P., Moncada, S., Bunting, S., Vane, J. R., Hamberg, M. & Samuelsson, B.(1976). Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature, 261, 558–560.PubMedCrossRefGoogle Scholar
  116. Needleman, P., Wyche, A & Raz, A. (1979). Platelet and blood vessel arachidonate metabolism and interactions. J. clin. Invest., 63, 345–349.PubMedCentralPubMedCrossRefGoogle Scholar
  117. Nijkamp, F. P., Moncada, S., White, H. L. & Vane, J R. (1977). Diversion of prostaglandin endoperoxide metabolism by selective inhibition of thromboxane A2 biosynthesis in lung, spleen or platelets. Eur. J. Pharmac., 44, 179–187.CrossRefGoogle Scholar
  118. Nugteren, D. H. & Hazelhof, E. (1973). Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim. Biophys. Acta., 326, 448–461.PubMedCrossRefGoogle Scholar
  119. O’Brien, J. R. (1968). Effects of salicylates on human platelets. Lancet, 1, 779–783.PubMedCrossRefGoogle Scholar
  120. O’Grady, J. & Moncada, S. (1978). Aspirin: A paradoxical effect on bleeding time. Lancet, 2, 780.PubMedCrossRefGoogle Scholar
  121. O’Grady, J., Warrington, S., Moti, M. J., Bunting, S., Flower, R. J., Fowle, A.S.E., Higgs, E. A. & Moncada, S. (1979). Effects of intravenous prostacyclin infusions in healthy volunteers — some preliminary observations. In Prostacyclin ed. Vane, J. R. & Bergstrom, S., pp 409–417. New York: Raven Press.Google Scholar
  122. Owen, T. L., Ehrhart, I. C., Weidner, W. J., Scott, J. B. & Haddy, F. J. (1975). Effects of indomethacin on local blood flow regulation in canine heart and kidney. Proc. Soc. exp. Biol. Med, 149, 871–876.PubMedCrossRefGoogle Scholar
  123. Pace-Asciak, C. R., Carrara, M. C., Rangaraj, G. & Nicolaou, K. G. (1978). Enhanced formation of PGI2, a potent hypotensive substance, by aortic rings and homogenates of the spontaneously hypertensive rat. Prostaglandins, 15, 1005–1012.PubMedCrossRefGoogle Scholar
  124. Patterson, R. H. & Kessler, J. (1969). A filter for micro-emboli in cardiopulmonary bypass. Circulation, 40, 160.Google Scholar
  125. Piper, P. J. & Vane, J. R. (1969). Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature, 223, 29–35.PubMedCrossRefGoogle Scholar
  126. Pomerantz, K., Sintetos, A. & Ramwell, P. (1978). The effect of prostacyclin on the human umbilical artery. Prostaglandins, 15, 1035–1044.PubMedCrossRefGoogle Scholar
  127. Quick, A. J. (1966). Salicylates and bleeding: the aspirin tolerance test. Am. J. med. Sci., 252, 265–269.PubMedCrossRefGoogle Scholar
  128. Rajah, S. M., Penny, S. & Kester, R. (1978). Aspirin and bleeding time. Lancet, 2, 1104.PubMedCrossRefGoogle Scholar
  129. Raz, A., Isakson, P. C., Minkes, M. S. & Needleman, P. (1977). Characterisation of a novel metabolic pathway of arachidonate in coronary arteries which generates a potent endogenous coronary vasodilator. J. biol. Chem., 252, 1123–1126.PubMedGoogle Scholar
  130. Remuzzi, G., Cavenaghi, A. E., Mecca, G., Donati, M. B. & De Gaetano, G. (1977). Prostacyclin (PGI2) and bleeding time in uremic patients. Thromb. Res., 11, 919–920.PubMedCrossRefGoogle Scholar
  131. Remuzzi, G., Cavenaghi, A. E., Mecca, G., Donati, M. B. & De Gaetano, G. (1978a). Human renal cortex generates prostacyclin-like activity. Thromb. Res., 12, 363–366.PubMedCrossRefGoogle Scholar
  132. Remuzzi, G., Misiani, R., Marchesi, D., Livio, M., Mecca, G., De Gaetano, G. & Donati, M. B. (1978b).Haemolytic-uraemic syndrome: Deficiency of plasma factor(s) regulating prostacyclin activity. Lancet, 2, 871–872.PubMedCrossRefGoogle Scholar
  133. Rosenblum, W. I. & El-Sabban, F. (1978). Enhancement of platelet aggregation by tranylcypromine in mouse cerebral microvessels. Circulation Res., 43, 238–241.PubMedCrossRefGoogle Scholar
  134. Roth, G. J. & Majerus, P. W. (1975). The mechanism of the effect of aspirin on human platelets. I. Acetylation on a particular fraction protein. J. clin Invest., 56, 624–632.PubMedCentralPubMedCrossRefGoogle Scholar
  135. Roth, G. J. & Siok, C. J. (1978). Acetylation of the NH2-terminal serine of prostaglandin synthetase by aspirin. J. biol. Chem., 253, 3782–3784.PubMedGoogle Scholar
  136. Saba, S. R. & Mason, R. G (1974). Studies of an activity from endothelial cells that inhibits platelet aggregation, serotonin release and clot retraction. Thromb. Res., 5, 747–757.PubMedCrossRefGoogle Scholar
  137. Schror, K., Moncada, S., Ubatuba, F. B. & Vane, J. R. (1978). Transformation of arachidonic acid and prostaglandin endoperoxides by the guinea-pig heart. Formation of RCS and prostacyclin. Eur. J. Pharmac., 47, 103–114.CrossRefGoogle Scholar
  138. Shimamoto, T., Kobayashi, M., Takahashi, T., Takashima, Y., Sakamoto, M. & Morooka, S. (1978). An observation of thromboxane A2 in arterial blood after cholesterol feeding in rabbits. Japan. Heart J., 19, 748–753.CrossRefGoogle Scholar
  139. Silberbauer, K., Sinzinger, H. & Winter, M. (1979). Prostacyclin activity in rat kidney stimulated by angiotensin II. Brit. J. exp. Pathol, 60, 38–44.Google Scholar
  140. Smith, J. B., Ingerman, C., Kocsis, J. J. & Silver, M. J. (1974). Formation of an intermediate in prostaglandin biosynthesis and its association with platelet release reaction. J. clin. Invest. 53, 1468–1472.PubMedCentralPubMedCrossRefGoogle Scholar
  141. Smith, J. B. & Willis, A. L. (1970). Formation and release of prostaglandins by platelets in response to thrombin. Brit. J. Pharmac., 40, 545p–546p.Google Scholar
  142. Smith, J. B. & Willis, A. L. (1971). Aspirin selectively inhibits prostaglandin production in human platelets. Nature New Biol, 231, 235–237.PubMedCrossRefGoogle Scholar
  143. Szczeklik, A., Gryglewski, R. J., Musial, J., Grodzinska, L., Serwonska, M. & Marcinkiewicz, E. (1978a). Thromboxane generation and platelet aggregation in survivals of myocardial infarction. Thromb. Diath. Haemorrh. (Stuttg.), 40, 66–74.Google Scholar
  144. Szczeklik, A., Gryglewski, R. J., Nizankowska, E., Nizankowski, R. & Musial, J. (1978b). Pulmonary and antiplatelet effects of intravenous and inhaled prostacyclin in man. Prostaglandins, 16, 651–660.CrossRefGoogle Scholar
  145. Szczeklik, A., Nizankowski, R., Skawinski, S., Szczeklik, J., Gluszko, P. & Gryglewski, R. J. (1979). Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet, 1, 1111–1114.PubMedCrossRefGoogle Scholar
  146. Tai, H. H. & Yuan, B. (1978). On the inhibitory potency of imidazole and its derivatives on thromboxane synthetase. Biochim. Biophys. Acta, 80, 236–242.Google Scholar
  147. Tateson, J. E., Moncada, S. & Vane, J. R. (1977). Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins, 13, 389–399.PubMedCrossRefGoogle Scholar
  148. Ubatuba, F. B., Moncada, S. & Vane, J. R. (1979). The effect of prostacyclin (PGI2) on platelet behaviour, thrombus formation in vivo and bleeding time. Thromb. Diath. Haemorrh. (Stuttg), 41, 425–434.Google Scholar
  149. Vane, J. R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirinlike drugs. Nature, 231, 232–235.Google Scholar
  150. Vane, J. R. (1976). The mode of action of aspirin and similar compounds. J. Allergy clin. Immunol, 58, 691–712.PubMedCrossRefGoogle Scholar
  151. Vermylen, J., Chamone, D. A. F. & Verstraete, M. (1979). Stimulation of prostacyclin release from vessel wall by BAYg6575, an antithrombotic compound. Lancet, 1, 518–520.PubMedCrossRefGoogle Scholar
  152. Verstraete, M. (1976). Are agents affecting platelet functions clinically useful? Am. J. Med., 81, 897–914.CrossRefGoogle Scholar
  153. Weber, P. C., Larsson, C., Anggard, E., Hamberg, M., Corey, E. J., Nicolaou, K. C. & Samuelsson, B. (1976). Stimulation of renin release from rabbit renal cortex by arachidonic acid and prostaglandin endoperoxides. Circulation Res., 39, 868–874.CrossRefGoogle Scholar
  154. Weiss, H. J., Aledort, L. M. & Kochwa, S. (1968). The effect of salicylates on the haemostatic properties of platelets in man. J. clin. Invest., 47, 2169–2180.PubMedCentralPubMedCrossRefGoogle Scholar
  155. Weiss, H. J. & Turitto, V. T. (1979). Prostacyclin (prostaglandin I2, PGI2) inhibits platelet adhesion and thrombus formation on subendothelium. Blood, 53, 244–250.PubMedGoogle Scholar
  156. Weston, M. J., Rubin, M., Hanid, A., Langley, P. G., Westaby, S. & Williams, R. (1977). Platelet function regulating agents. Experimental data relevant to hepatic disease. In Thromboembolism-a new approach to therapy ed. Mitchell, J. R. A. & Domenet, J. G., pp 76–82. London: Academic Press.Google Scholar
  157. Whorton, A. R., Misono, K., Hollifield, J., Frolich, J. C., Inagami, T. & Oates, J. A. (1977a). Prostaglandins and renin release. I. Stimulation of renin release from rabbit renal cortical slices by PGI2. Prostaglandins, 14, 1095–1104.PubMedCrossRefGoogle Scholar
  158. Whorton, A. R., Smigel, M., Oates, J. A. & Frolich, J. C. (1977b). Evidence for prostacyclin production in renal cortex. Prostaglandins, 13, 1021.Google Scholar
  159. Woods, H. F., Ash, G., Weston, M. J., Bunting, S., Moncada, S. & Vane, J. R. (1978). Prostacyclin can replace heparin in haemodialysis in dogs. Lancet, 2, 1075–1077.PubMedCrossRefGoogle Scholar
  160. Zenser, T. V., Herman, C. A., Gorman, R. R. & Davis, B. B. (1977). Metabolism and action of the prostaglandin endoperoxide PGH2 in rat kidney. Biochem. Biophys. Res. Commun., 79, 357–363.PubMedCrossRefGoogle Scholar

Copyright information

© The contributors 1980

Authors and Affiliations

  • S. Moncada
    • 1
  • J. R. Vane
    • 1
  1. 1.Wellcome Research Laboratories Langley CourtBeckenhamEngland

Personalised recommendations